



## The Tumor Microenvironment Polarization as a Goal of Cancer Immunotherapy

Guest Editors:

### **Dr. Ryszard Smolarczyk**

Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej Street 15, 44-102 Gliwice, Poland

### **Dr. Justyna Czapla**

Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej Street 15, 44-102 Gliwice, Poland

Deadline for manuscript submissions:  
**closed (31 August 2023)**

### **Message from the Guest Editors**

Successful immunotherapy depends on efficient activation of host immune cells to fight against cancer but also on sustained immunostimulatory milieu. The tumor microenvironment (TME) which consists of non-malignant cells such as stromal cells (cancer associated fibroblasts (CAF)), immune and inflammatory cells (neutrophils, macrophages, NK cells, lymphocytes), cells of the vascular system, creates supportive and immunosuppressive milieu for tumor growth. Reversal of tumor promoting properties of the TME towards tumoricidal and immunostimulatory is promising strategy to improve response to immunotherapy. Turning “cold” tumor milieu into “hot” one enhances immunogenicity, restores immune cytotoxic activity and favors anti-tumor immunity.

This Special Issue aims to highlight recent advances on microenvironment-polarizing combinations for cancer immunotherapy.

We are pleased to invite you to submit an original research or state of art review on all aspects of the TME alterations to improve immunotherapy outcomes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)